New World tegumentar leishmaniasis: chemotherapeutic activity of rifampicin in humans and experimental murine model.
Daily doses of 0.5 mg of rifampicin given intraperitoneally to mice after a challenge dose of 104 amastigotes of L. amazonensis led to a significant reduction of the size of local lesions. On the other hand, daily doses of 20 mg/kg to children or 1200 mg to adult patients infected with L. braziliensis did not bring any sign of improvement after 30 days of treatment. Our results formally contradict rifampicin as an alternative drug in Leishmania braziliensis infections.
Do Valle
T Z
TZ
Departamento de Protozoologia, Instituto Oswaldo Cruz, Fiocruz, Rio De Janeiro, Brasil.
Oliveira Neto
M P
MP
Schubach
A
A
Lagrange
P H
PH
Da Costa
S C
SC
D000293:Adolescent; D000328:Adult; D000818:Animals; D002648:Child; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007891:Leishmania / Q000302:isolation & purification*; D007892:Leishmania braziliensis / Q000302:isolation & purification*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology; D007917:Leprostatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use*
D007917:Leprostatic Agents; D012293:Rifampin